Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Active funds frequently lag behind due to fees and manager risk, while index funds provide broad exposure with lower costs and smoother performance.
22,822 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
A leading LNG stock jumped 32% this stock year, investor took profits, and a massive exit followed. Here’s how to und...
A Nobel Prize–winning economist says U.S. democracy hinges on two policy shifts tied to AI and inequality. He outline...
Private credit making investors nervous highlights how market risk, defaults, and liquidity affect BDCs. Yet Main Str...
A mid-size fund reduced its TriMas stake by about $5 million after a strong run, but didn’t exit the position entirel...
The federal debt breached $39 trillion this week as lawmakers debated a constitutional fix that failed to pass. The p...
Investors spotted a notable move in the mining space as Coeur Mining stock popped after an earnings beat. This piece ...
LegalZoom stock slipped today as markets digested the latest quarter. This article breaks down the drivers behind the...
The AI boom often centers on GPUs and big models, but the true mover is the network that ties data and compute togeth...
CoreWeave has rallied this year as AI infrastructure demand heats up. This article breaks down why the stock around t...
As 2026 reshapes real estate marketing, a new ranking spotlights the 10 best real estate marketing firms. Agents and ...
The chatter around prediction markets booming is loud, but this guide helps you focus on three AI stocks with real up...